XOMA Royalty Corporation (NASDAQ:XOMA) Receives $60.60 Average Target Price from Brokerages

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) have been assigned an average recommendation of “Hold” from the five brokerages that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $60.60.

A number of brokerages recently issued reports on XOMA. Leerink Partners lowered their price target on shares of XOMA Royalty from $58.00 to $45.00 and set an “outperform” rating for the company in a research report on Thursday, December 11th. Zacks Research downgraded shares of XOMA Royalty from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 18th. Benchmark reiterated a “buy” rating on shares of XOMA Royalty in a report on Friday, December 12th. Weiss Ratings restated a “hold (c-)” rating on shares of XOMA Royalty in a research note on Monday, December 29th. Finally, Stifel Nicolaus set a $50.00 price objective on XOMA Royalty in a research report on Friday, December 12th.

XOMA Royalty Trading Up 2.9%

XOMA opened at $27.21 on Monday. The company has a quick ratio of 3.91, a current ratio of 3.91 and a debt-to-equity ratio of 1.07. XOMA Royalty has a 52 week low of $18.35 and a 52 week high of $39.92. The stock has a market cap of $336.86 million, a PE ratio of 36.77 and a beta of 0.89. The business has a 50 day moving average of $29.80 and a 200-day moving average of $31.18.

XOMA Royalty (NASDAQ:XOMA) last posted its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.33). XOMA Royalty had a return on equity of 2.91% and a net margin of 32.28%.The firm had revenue of $9.35 million during the quarter, compared to the consensus estimate of $11.47 million. Equities research analysts predict that XOMA Royalty will post -1.41 earnings per share for the current fiscal year.

Insider Buying and Selling at XOMA Royalty

In other news, CEO Owen Hughes purchased 100,000 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The shares were bought at an average price of $25.05 per share, for a total transaction of $2,505,000.00. Following the purchase, the chief executive officer directly owned 102,000 shares in the company, valued at approximately $2,555,100. This trade represents a 5,000.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 9.10% of the stock is owned by insiders.

Institutional Investors Weigh In On XOMA Royalty

Large investors have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its stake in XOMA Royalty by 3,436.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 756 shares during the period. Tower Research Capital LLC TRC boosted its holdings in XOMA Royalty by 203.1% in the second quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,523 shares during the last quarter. JPMorgan Chase & Co. grew its position in XOMA Royalty by 13.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 543 shares during the period. Raymond James Financial Inc. bought a new stake in XOMA Royalty in the 2nd quarter worth approximately $116,000. Finally, BNP Paribas Financial Markets raised its stake in XOMA Royalty by 266.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock valued at $124,000 after buying an additional 2,346 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.